AF solution
Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
The study investigates the modulation of ACE2 expression, a key receptor for SARS-CoV-2, to combat COVID-19. Using human embryonic stem cell-derived islet organoids, animal models, and COVID-19 patient data, researchers discovered that fibroblast growth factor 7 (FGF7) enhances ACE2 expression in islets, leading to increased susceptibility to SARS-CoV-2 infection and impaired insulin secretion. They found that FGF7 interacts with FGF receptor 2 (FGFR2) and FGFR1 to upregulate ACE2 expression predominantly in β cells. Inhibiting FGFR counteracted FGF7-induced ACE2 upregulation, reducing viral infection and replication in islets. Clinical data showed diabetic patients with severe COVID-19 symptoms had elevated serum FGF7 levels. Animal experiments revealed SARS-CoV-2 infection increased pancreatic FGF7 levels, reducing insulin concentrations. The study suggests controlling FGF7 as a potential strategy to regulate ACE2, protecting islets from SARS-CoV-2 infection and preventing diabetes progression in COVID-19.
Keywords: Human islet organoids, ACE2 expression, SARS CoV-2, diabetes
@ 2024 . All rights reserved
@ 2024 . All rights reserved
Log in to MyLab and
download your gift voucher from the ‘Vouchers’ menu!
Thank you for your continued trust and partnership.
We look forward to serving you with excellence.